Mersana Therapeutics, Inc.
Mersana Therapeutics is an oncology company developing new therapeutics based on powerful glycomimetic technologies invented at the Massachusetts General Hospital (MGH) (Boston, MA). The Company has a pipeline of novel cancer compounds. External collaborations, including relationships with large biopharmaceutical companies, leverage Mersana's technology in other areas such as large molecule (e.g. protein and RNAi) therapeutics.
Mersana's proprietary technologies are engineered to mimic properties of sugar molecules found throughout the body without eliciting the side effects characteristic of carbohydrates. Fleximer®, a novel glycomimetic biodegradable polymer, shields proteins and small molecules from the immune system or other biological receptors, to improve efficacy and avoid side effects or toxicity. For small molecule drugs, Fleximer increases solubility of compounds and directs drugs into tumors instead of healthy tissue. For proteins, Fleximer preserves therapeutic activity, improves bioavailability, and allows less frequent dosing.
Mersana's core technologies are licensed exclusively from the MGH. Mersana's proprietary Fleximer® technology is covered by issued and pending patents worldwide Complementary technologies, including those for linking Fleximer to therapeutics, are covered by several other patent families pending worldwide.